Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B387a322e0fc1e8e66e8d4e0f6a3fdb09> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B387a322e0fc1e8e66e8d4e0f6a3fdb09 NCIT_P378 "NCI" @default.
- B387a322e0fc1e8e66e8d4e0f6a3fdb09 type Axiom @default.
- B387a322e0fc1e8e66e8d4e0f6a3fdb09 annotatedProperty IAO_0000115 @default.
- B387a322e0fc1e8e66e8d4e0f6a3fdb09 annotatedSource NCIT_C78194 @default.
- B387a322e0fc1e8e66e8d4e0f6a3fdb09 annotatedTarget "The hydrochloride salt form of an orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome." @default.